US states are pulling various levers to address rising drug prices.

American states are actively exploring drug pricing legislation despite a Congressional gridlock. 

A new analysis from @Deloitte finds states nationwide are pulling various levers to address drug pricing, and advancing bills focused on numerous topics. Many states have passed — or are considering — measures such as transparency requirements for price increases, importation, value-based contracting and more.

The analysis concludes the shift to value-based contracting, at both the state level and in the private sector, is likely to continue gaining momentum.

Since 2018, several states, including Colorado, Michigan, and Oklahoma have adopted alternative payment models focused on patient outcomes.